Mesoblast Moves Forward with the Next Phase of Clinical Trials Using "off-the-Shelf" Stem Cells
News Jul 17, 2007
Mesoblast Limited has announced the commencement of its first United States-based clinical trial using allogeneic, "off-the-shelf" or universal donor, adult stem cells for patients with intervertebral disc disease and requiring spinal fusion.
Mesoblast Founder, Professor Silviu Itescu, said: "We have been delighted by the strong interim results from the Pilot Trial at The Royal Melbourne Hospital for fracture repair using patients' own, or autologous, stem cells, All 10 patients have now safely recieved stem cell implantation.”
"The results from the Pilot Trial have now enabled Mesoblast to progress to the next phase of clinical development, using allogeneic (universal donor) cells.”
"We are excited to be commencing the allogeneic cells will be undertaken at the Hospital for Special Surgery (HSS) in New York, an Institution in orthopaedic treatments."
The trial's Principle Investigator is Joseph M. Lane, M.D., Chief of the Metabolic Bone Disease Service and Attending Orthopaedic Surgeon, Hospital for Special Surgery. He is also Medical Director of the Osteoporosis Prevention Center and Associate Director of the Trauma Service.
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.